Skip to main content
. Author manuscript; available in PMC: 2015 Mar 10.
Published in final edited form as: Drug Metab Lett. 2014 Jul;7(2):83–95. doi: 10.2174/1872312808666140129123210

Fig (2).

Fig (2)

Two point screening of herbal medicines where 0.2 and 2.0 mg/ml of each herbal extract was evaluated for inhibitory effects on each of the five CYPs, 1A2, 2C9, 2C19, 2D6 and 3A4. For each of these CYPs, a positive control diagnostic inhibitor was used, alpha-nathoflvaone (ANF, 0.01 and 0.10 μM) for CYP1A2, sulfaphenazole (SPZ, 1.0 and 10.0 μM) for CYPs 2C9 and 2C19, quinidine (QND, 0.01 and 0.1 μM) for CYP2D6 and ketoconazole (KTZ, 0.01 and 0.1 μM) for CYP3A4. H. hemerocallidea capsule (T41) and powdered leaves (T30), L. frutescens tablets (T50) and tea cut (T79), T. officinale root (T66), E. purpurea capsules (T60), M. oleifera powdered leaves (T80) and GABA capsule (T70).